42988-32-9

Basic information

• Product Name: N-(2-aminoethyl)benzenesulfonamide
• Synonyms: N-(2-aminoethyl)benzenesulfonamide
• CAS NO: 42988-32-9
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.25808
• Mol File: 42988-32-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 81-83 °C
• Boiling Point: 353.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.249±0.06 g/cm3(Predicted)
• PKA: 11.21±0.10(Predicted)
• CAS DataBase Reference: N-(2-aminoethyl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-aminoethyl)benzenesulfonamide(42988-32-9)
• EPA Substance Registry System: N-(2-aminoethyl)benzenesulfonamide(42988-32-9)

Safety Data

• Hazardous Substances Data: 42988-32-9(Hazardous Substances Data)

Upstream product

• 6274-53-9 N-(2-(phenylsulfonamido)ethyl)acetamide 
• 970-88-7 2,4-dinitrophenyl benzenesulfonate 
• 107-15-3 ethylenediamine 
• 98-09-9 benzenesulfonyl chloride 
• 2576-47-8 2-bromoethylamine hydrobromide 

Downstream Products

• 56202-68-7 N-[2-(2-Hydroxy-2-phenyl-ethylamino)-ethyl]-benzenesulfonamide 
• 53672-03-0 N-{2-[2-Hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-benzenesulfonamide 
• 58027-20-6 2-{4-[3-(2-Benzenesulfonylamino-ethylamino)-2-hydroxy-propoxy]-phenyl}-acetamide 
• 53671-40-2 N-{2-[3-(2-Cyano-phenoxy)-2-hydroxy-propylamino]-ethyl}-benzenesulfonamide 
• 53670-97-6 3-<(2-benzenesulfonamidoethyl)amino>-1-phenoxypropan-2-ol 
• 83019-50-5 3--1-phenoxypropan-2-ol 
• 53672-78-9 N-{2-[3-(3,4-Dihydroxy-phenoxy)-2-hydroxy-propylamino]-ethyl}-benzenesulfonamide 
• 53672-76-7 N-{2-[2-Hydroxy-3-(4-hydroxy-3-hydroxymethyl-phenoxy)-propylamino]-ethyl}-benzenesulfonamide 
• 53672-67-6 N-{2-[2-Hydroxy-3-(4-hydroxy-3-methoxy-phenoxy)-propylamino]-ethyl}-benzenesulfonamide 
• 1233940-84-5 N-[2-{((8-hydroxyquinolin-7-yl)methyl)amino}ethyl]benzenesulfonamide 

Relevant articles and documents

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

A new series of N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives 11a-o were designed and synthesized based on our previous works. The new series was tested for its anticancer and anti-inflammatory effects. The anticancer profile of

Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF

Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600EB-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600EB-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their V600EB-RAF inhibitory effect at single dose (10 μM). Compounds with high percent inhibition were tested to determine their IC50 over V600EB-RAF. Compounds 34e and 35 showed the highest inhibitory effect with IC50 values of 0.085 μM and 0.080 μM, respectively. Headed for excessive biological evaluation, the synthesized derivatives were tested over sixty diverse human cancer cell lines. Only compound 35 emerged as a potent cytotoxic agent against different panel of human cancer cell lines.